• Nystatin (Fungicidin): Advanced Antifungal Workflows & Insig

  2026-05-09

  Nystatin (Fungicidin) from APExBIO empowers antifungal research with robust activity, reproducible protocols, and new synergy strategies. Explore optimized workflows, troubleshooting tips, and the latest evidence on potentiating efficacy against Candida and Aspergillus species.

• BMS 309403: Optimizing FABP4 Inhibition in Atherosclerosis R

  2026-05-09

  BMS 309403, a potent and selective FABP4 inhibitor, streamlines the dissection of lipid metabolism and inflammatory pathways in atherosclerosis and type 2 diabetes research. This article delivers protocol-anchored insights, troubleshooting strategies, and translational workflow enhancements that empower researchers to unlock new mechanistic and therapeutic possibilities.

• NUAK1 Inhibition Lowers Pathological Tau Phosphorylation in

  2026-05-08

  This study establishes a strong association between phosphorylation of tau at Ser356 and Alzheimer’s disease progression, and demonstrates that the NUAK1/2 inhibitor WZ4003 selectively reduces p-tau Ser356 in human brain slice cultures. The findings provide mechanistic evidence for targeting NUAK1-mediated tau phosphorylation and offer refined guidance for translational research on tauopathies.

• Cy3 Goat Anti-Human IgG (H+L) Antibody: High-Sensitivity Det

  2026-05-07

  The Cy3 Goat Anti-Human IgG (H+L) Antibody enables highly sensitive detection of human immunoglobulins in multiple immunoassay formats. This polyclonal, affinity-purified secondary antibody, conjugated with Cy3, delivers robust signal amplification and specificity. Its validated performance across immunofluorescence, immunohistochemistry, flow cytometry, and ELISA makes it a reliable reagent for translational and diagnostic applications.

• Tobramycin: Strategic Leverage for Translational Microbiolog

  2026-05-07

  This thought-leadership article provides translational researchers with a mechanistically grounded, evidence-driven roadmap for deploying Tobramycin as a core asset in Gram-negative antibiotic and resistance studies. By integrating comparative in vitro data, practical protocol insights, and a forward-looking perspective on resistance dynamics, the article advances the conversation beyond standard product guides, positioning APExBIO’s Tobramycin as a benchmark for experimental rigor and reproducibility.

• URB597 (KDS-4103): Selective FAAH Inhibition for Neuroscienc

  2026-05-06

  URB597, also known as KDS-4103, is a potent and selective FAAH inhibitor that elevates brain anandamide levels without direct cannabinoid receptor activity. Its high specificity and robust in vivo activity make it a key tool for endocannabinoid signaling and neuroplasticity research.

• Y-27632 dihydrochloride (SKU A3008): Reliable ROCK Inhibitor

  2026-05-06

  This article delivers evidence-based guidance on using Y-27632 dihydrochloride (SKU A3008) to address core challenges in cell viability, proliferation, and cytotoxicity assays. With a scenario-driven approach, it demonstrates how this selective ROCK inhibitor enhances reproducibility and data quality for biomedical researchers. Explore validated workflows, protocol parameters, and vendor selection insights anchored by quantitative literature and product data.

• L-Glutathione Reduced: Redox Modulator in Metabolic Research

  2026-05-05

  Explore the pivotal scientific advances linking L-Glutathione Reduced to metabolic reprogramming and redox control in cancer and cardiovascular research. This article integrates mechanistic insights with assay design, offering a fresh perspective on reduced glutathione’s applications.

• PreScission Protease: Precision HRV 3C Cleavage in Protein P

  2026-05-05

  PreScission Protease (PSP) delivers ultra-specific HRV 3C cleavage, enabling reliable fusion tag removal even in low-temperature workflows. Its optimized design empowers sensitive protein purification and advanced studies, such as nuclear condensate biology.

• Machine Learning Unlocks New Senolytics for Targeting Senesc

  2026-05-04

  The referenced study demonstrates how machine learning can identify novel senolytic compounds by leveraging published data and computational screening. This approach reduces discovery costs and expands the toolkit for selectively eliminating senescent cells, with implications for cancer, aging, and disease models.

• LY2886721: Potent Oral BACE1 Inhibitor for Alzheimer’s Resea

  2026-05-04

  LY2886721 is a nanomolar-potency, furothiazine-based oral BACE inhibitor that robustly suppresses amyloid-beta production via targeted BACE1 enzyme inhibition. Evidence supports its use in both in vitro and in vivo Alzheimer’s disease models, demonstrating substantial amyloid reduction without impairment of synaptic function at moderate exposures.

• Jiawei Weijin Decoction Targets SPP1 to Suppress NSCLC Metas

  2026-05-03

  Xu et al. comprehensively investigated Jiawei Weijin Decoction (JWWJD) in non-small cell lung cancer (NSCLC), combining network pharmacology, bioinformatics, and experimental validation. The study identifies curcumol as a key active compound that directly downregulates SPP1, thereby inhibiting tumor growth and metastasis, with implications for future therapeutic strategies.

• BMS 309403: Selective FABP4 Inhibitor for Atherosclerosis Re

  2026-05-02

  BMS 309403 is a potent and selective FABP4 inhibitor with a Ki below 2 nM, showing efficacy in experimental models of atherosclerosis and type 2 diabetes. Its specific inhibition of FABP4 modulates lipid metabolism and macrophage-driven inflammation, supporting its use in advanced metabolic and cardiovascular research.

• SNORA38B Drives NSCLC Progression and Immunotherapy Response

  2026-05-02

  The referenced study identifies SNORA38B as a key oncogenic small nucleolar RNA in non-small cell lung cancer (NSCLC), promoting tumor growth and immune suppression via the GAB2/AKT/mTOR pathway. Targeting SNORA38B with locked nucleic acids was shown to both inhibit tumorigenesis and sensitize tumors to immune checkpoint blockade, highlighting its potential as a therapeutic target and biomarker.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-05-01

  Schwartz’s dissertation critically re-examines in vitro approaches for assessing anti-cancer drug responses, distinguishing proliferative arrest from cell death with new clarity. This improved framework advances the interpretation of agents like Wee1 kinase inhibitors, informing both experimental design and translational research.

16173 records 1/1079 page Next 12345 下5页 Last page